The incidence of hypoglycemia with SGLT2i overall tends to be similar to that with placebo or non- SGLT2i antidiabetic drugs, such as metformin, glitazones and DDP4i, and lower when compared with insulin or SUs [179]. This evidence concerns the gene INS and Hypoglycemia.